Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells.

导出 OA

翻译打印收藏纠错

作者： Yangwei,Fan ^[1] ; Ke,Ma ^[2] ; Jiayu,Jing ^[1] ; Chuying,Wang ^[1] ; Yuan,Hu ^[1] ; Yu,Shi ^[1] ; Enxiao,Li ^[1] ; Qianqian,Geng ^[3]

作者单位： Department of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an710061, China. ^[1] Department of Medical Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou450052, China. ^[2] Department of Nuclear Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an710061, China. ^[3]

关键词 MDM2 MDMX MDR breast cancer p53

DOI 10.7150/jca.32765

PMID 31892970

发布时间 2020-10-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览5

Journal of Cancer

2020年11卷1期

25-40页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells.

Journal of Cancer

相似文献

Journal of Cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells.

Journal of Cancer

相似文献

Journal of Cancer

相关期刊

检索历史清除